Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary
Immunic reported a net loss of $42.3M, up 65% YoY, with operating expenses rising 67%. R&D costs increased 20%, while G&A expenses surged 225% due to personnel costs. Top-line data from Phase 3 trials is expected in December 2026. According to the company, Phase 3 progressive MS trial initiation is ongoing, with first-patient-enrolled expected in the first half of 2027.
How this was made

The 30-second read
Why it matters
The earnings miss and expense increase are likely to depress the stock in the near term, though upcoming trial readouts could provide a catalyst.
Market read
Primary earnings disclosure for a micro‑cap biotech; short‑term downside risk with potential longer‑term upside from trial data.
What to watch
The company is advancing multiple Phase 3 trials, which could offset short-term earnings weakness if data are positive.
Background
Immunic filed its Form 10‑Q for Q3 2026, detailing financial results and trial timelines.
Ticker impact
Immunic reported a Q3 2026 net loss of $42.3M and EPS of -$0.99, widening from the prior quarter.
likely pressure as the market prices in the larger loss and expense surge
Earnings miss and expense growth are fresh primary data that typically drive short-term price declines.
Market effects
Biotech sector may see modest pullback as a peer reports higher R&D spend and loss.
US-listed biotech stocks could face slight downside pressure.
Limited; impact confined to Immunic and closely related biotech peers.
Counterpoint
If the market overreacts to the loss, a bounce could occur on the upcoming Phase 3 trial data in December.
Key entities
- companyImmunic, Inc.
US‑listed biotech company reporting Q3 2026 results.


